AstraZeneca taps insitro's AI platform in a $40 million upfront deal for MASH and heart-muscle diseases

AstraZeneca has agreed to pay insitro $40 million upfront, and potentially much more later, to use the AI company's discovery platform against a serious liver disease and diseases of the heart muscle. Insitro will hunt for biological targets; AstraZeneca will take any selected programmes into the clinic and keep exclusive worldwide rights to advance them.

The deal

AstraZeneca said on Thursday, Oct. 15, that it has signed a strategic drug-discovery collaboration and licensing agreement with insitro, a privately held artificial-intelligence therapeutics company based in South San Francisco. The work targets metabolic dysfunction-associated steatohepatitis, known as MASH, and cardiomyopathies — diseases of the heart muscle — which both companies described as complex, heterogeneous conditions with significant unmet need.

Under the agreement, insitro will use its Virtual Human AI platform to identify causal disease biology in both indications and to advance targets nominated by AstraZeneca from discovery through to a development candidate. AstraZeneca will lead clinical development, regulatory work and commercialization, according to insitro, and will have exclusive worldwide rights to advance selected programmes identified under the collaboration, according to AstraZeneca.

The platform, as AstraZeneca described it, brings together large-scale human and cellular data with AI-enabled target identification and medicine design. Insitro said that in diseases like MASH and cardiomyopathies a single diagnostic label can cover patients whose underlying biology differs, which is the setting where its machine-learning tools on human data are most useful.

What each side is paid

Insitro will receive an upfront payment of $40 million. It is also eligible for up to about $1.46 billion in milestones and for single-digit royalties on global commercial sales. AstraZeneca's release describes those milestones as development and commercial; insitro's release includes discovery milestones in the same about-$1.46 billion figure. Neither company named individual programmes or disclosed how the milestones are split across the two disease areas.

Reuters, citing the drugmaker, also called the collaboration multi-year and said AstraZeneca will run and fund future clinical trials once candidates are ready — a point that matches the division of labor in the company releases.

Why the companies say it matters

Choosing the right biological target is one of the hardest steps in drug discovery, AstraZeneca said. Sharon Barr, the company's executive vice president and head of BioPharmaceuticals research and development, said the collaboration is meant to use advanced AI to identify the biological drivers of disease and support faster discovery of novel targets. Daphne Koller, insitro's founder and chief executive, said MASH and cardiomyopathies are prevalent and underdiagnosed diseases where high-content data can help uncover disease drivers, and that pairing insitro's platform with AstraZeneca's pharmaceutical scale could speed programmes toward patients.

Insitro, founded in 2018, said it has raised more than $750 million from investors and already collaborates with Bristol Myers Squibb, Eli Lilly and Gilead. Reuters reported that the company recently expanded its Bristol Myers Squibb partnership on ALS targets and has worked with Lilly on AI models that predict how small molecules behave in living organisms.

How the shares traded

AstraZeneca's American depositary shares closed at $166.68 on Thursday, up about 2.9% from Wednesday's close of $162.03, and slipped about 0.8% on Friday to $165.41, by TickerGrove's calculation from Nasdaq data. About 4.4 million shares changed hands on Thursday, above Wednesday's about 3.3 million. Markets were closed on Saturday, when this article was prepared.

What is not yet known

The companies have not named any nominated targets, development candidates or clinical timelines. The collaboration is a discovery-stage research and licensing agreement, not a merger or an approved medicine. Whether any programme reaches patients depends on later research, trials and regulatory decisions that have not begun under this deal.